Wang Christopher Min Fang 4

What Happened Christopher Wang, a director of STAAR SURGICAL CO (STAA), was granted a derivative award on June 18, 2026: options covering 11,145 shares (transaction code A). The Form 4 lists the acquisition price as $0.00 (reflecting an equity award/option grant); no immediate cash value or exercise price is provided in the filing. This was a grant of equity rather than an open-market purchase or sale.

Key Details

• Transaction date: June 18, 2026 (reported on a Form 4 filed June 23, 2026).
• Transaction type/code: Award/Grant (A); 11,145 shares (derivative security).
• Price shown on filing: $0.00 (standard for a grant/award entry; not a measure of economic value here).
• Shares owned after transaction: not specified in the summary provided — see the official Form 4 for post-transaction holdings.
• Footnote: F1 — These stock options vest in full on the earlier of June 18, 2027 or the issuer's 2026 annual meeting of shareholders.
• Timeliness: Filing date is June 23, 2026 for a June 18 transaction; consult the official filing for any timeliness notation.

Context This was an equity award (options grant) to a director, not an exercised option or sale. The options vest in full by the earlier of one year or the 2026 annual meeting, per the footnote. Grants to directors are common as compensation and do not, by themselves, indicate whether the insider will buy or sell shares later; they represent potential future equity if vesting and any exercise conditions are met. For full details (exercise price, post-transaction holdings, or additional footnotes), refer to the complete Form 4 filing (Accession: 0000921895-26-001649).